People and Business: On the move
DR DAVID U'PRICHARD, who stepped down as chairman of research and development at SmithKline Beecham recently after only 18 months in the job, has popped up as a non-executive director of RiboTargets, a Cambridge-based biotechnology company.
Dr U'Prichard, 50, was international research director at Zeneca Pharmaceuticals between 1994 and 1997, when he moved to SmithKline Beecham.
RiboTargets was formed in July 1997 to commercialise revolutionary developments in the understanding of RNA, the link between the genetic information contained in DNA and protein synthesis.
The company is involved in developing a range of drugs to combat HIV and Hepatitis C.
E-mail: j.willcock@independent.co.uk
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies